ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans

Bone

Volumn 49, Issue 2, 2011, Pages 233-241

  John, Markus R ^a   Widler, Leo ^a,b   Gamse, Rainer ^a,b   Buhl, Thomas ^a,b   Seuwen, Klaus ^a,b   Breitenstein, Werner ^a,b   Bruin, Gerard J M ^a   Belleli, Rossella ^a   Klickstein, Lloyd B ^a,b   Kneissel, Michaela ^a,b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Bone formation; Calcilytics; Osteoporosis; Parathyroid hormone; Teriparatide

Indexed keywords

ATF 936; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RECOMBINANT PARATHYROID HORMONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MINERALIZATION; CANCELLOUS BONE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; MAXIMUM PLASMA CONCENTRATION; METAPHYSIS; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; RAT; SINGLE DRUG DOSE; TIBIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TRABECULAR BONE;

ADULT; ANABOLIC AGENTS; ANIMALS; BONE AND BONES; BONE DENSITY; CALCIUM; DOGS; FEMALE; HUMANS; MALE; MOLECULAR STRUCTURE; PARATHYROID HORMONE; RATS; RATS, WISTAR; RECEPTORS, CALCIUM-SENSING;

EID: 79958767669     PISSN: 87563282     EISSN: 87563282     Source Type: Journal    
DOI: 10.1016/j.bone.2011.04.007     Document Type: Article

References (41)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis [Conference report]. Am J Med 1993, 94(6):646-650.
2. Miller P.D. Anti-resorptives in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008, 22(5):849-868.
3. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282(7):637-645.
4. Häuselmann H.J., Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 2003, 14(1):2-12.
5. Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE), Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19(8):1241-1249.
6. Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006, 28(2):151-173.
7. Rubin M.R., Cosman F., Lindsay R., Bilezikian J.P. The anabolic effects of parathyroid hormone. Osteoporos Int 2002, 13(4):267-277.
8. Dempster D.W., Cosman F., Parisien M., Shen V., Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993, 14(6):690-709.
9. Lee M., Partridge N.C. Parathyroid hormone signaling in bone and kidney. Curr Opin Nephrol Hypertens 2009, 18(4):298-302.
10. Goltzman D. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch Biochem Biophys 2008, 473(2):218-224.
11. Qin L., Raggatt L.J., Partridge N.C. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab 2004, 15(2):60-65.
12. Jilka R.L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007, 40(6):1434-1446.
13. Kramer I., Keller H., Leupin O., Kneissel M. Does osteocytic SOST suppression mediate PTH bone anabolism?. Trends Endocrinol Metab 2010, 21(4):237-244.
14. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344(19):1434-1441.
15. Chen P., Miller P.D., Recker R., Resch H., Rana A., Pavo I., et al. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 2007, 22(8):1173-1180.
16. Watts N.B., Miller P.D., Kohlmeier L.A., Sebba A., Chen P., Wong M., et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. J Bone Miner Res 2009, 24(6):1125-1131.
17. Hodsman A.B., Hanley D.A., Ettinger M.P., Bolognese M.A., Fox J., Metcalfe A.J., et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88(11):5212-5220.
18. Greenspan S.L., Bone H.G., Ettinger M.P., Hanley D.A., Lindsay R., Zanchetta J.R., et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007, 146(5):326-339.
19. Misof B.M., Roschger P., Cosman F., Kurland E.S., Tesch W., Messmer P., et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003, 88(3):1150-1156.
20. Miller P.D. Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep 2008, 6(1):12-16.
21. Morley P. Delivery of parathyroid hormone for the treatment of osteoporosis. Expert Opin Drug Deliv 2005, 2(6):993-1002.
22. Nemeth E.F. The search for calcium receptor antagonists (calcilytics). J Mol Endocrinol 2002, 29(1):15-21.
23. Gowen M., Stroup G.B., Dodds R.A., James I.E., Votta B.J., Smith B.R., et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 2000, 105(11):1595-1604.
24. Kumar S., Liang X., Vasko J.A., Stroup G.B., Hoffman S.J., Vaden V.R., et al. Oral Treatment with the Calcium Receptor Antagonist SB-423557 Causes PTH Release in Multiple Species and Positive Bone Forming Effects in the Rat [Abstract S386], ASBMR 29th Annual Meeting. J Bone Miner Res 2007, 22:S123. 10.1002/jbmr.5650221404.
25. Kumar S., Matheny C.J., Hoffman S.J., Marquis R.W., Schultz M., Liang X., et al. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone 2010, 46(2):534-542.
26. Widler L., Altmann E., Beerli R., Breitenstein W., Bouhelal R., Buhl T., et al. 1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists. J Med Chem 2010, 53(5):2250-2263.
27. Ettinger B., San Martin J., Crans G., Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19(5):745-751.
28. Kurland E.S., Cosman F., McMahon D.J., Rosen C.J., Lindsay R., Bilezikian J.P. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85(9):3069-3076.
29. Finkelstein J.S., Hayes A., Hunzelman J.L., Wyland J.J., Lee H., Neer R.M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349(13):1216-1226.
30. Finkelstein J.S., Leder B.Z., Burnett S.M., Wyland J.J., Lee H., de la Paz A.V., et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006, 91(8):2882-2887.
31. Lane N.E., Sanchez S., Modin G.W., Genant H.K., Pierini E., Arnaud C.D. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998, 102(8):1627-1633.
32. Rehman Q., Lang T.F., Arnaud C.D., Modin G.W., Lane N.E. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2003, 14(1):77-81.
33. Hodsman A.B., Fraher L.J., Ostbye T., Adachi J.D., Steer B.M. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 1993, 91(3):1138-1148.
34. Hodsman A.B., Bauer D.C., Dempster D.W., Dian L., Hanley D.A., Harris S.T., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005, 26(5):688-703.
35. Rubin M.R., Bilezikian J.P. Parathyroid hormone as an anabolic skeletal therapy. Drugs 2005, 65(17):2481-2498.
36. Glover S.J., Eastell R., McCloskey E.V., Rogers A., Garnero P., Lowery J., et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2009, 45(6):1053-1058.
37. Fox J., Miller M.A., Stroup G.B., Nemeth E.F., Miller S.C. Plasma levels of parathyroid hormone that induce anabolic effects in bone of ovariectomized rats can be achieved by stimulation of endogenous hormone secretion. Bone 1997, 21(2):163-169.
38. Seeman E., Delmas P.D. Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab 2001, 12(7):281-283.
39. Physicians' Desk Reference 2005, 1842. Thomson PDR, Montvale, NJ. 59th ed.
40. Dobnig H., Turner R.T. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997, 138(11):4607-4612.
41. Endo I., Onishi Y., Kido R., Kurahashi K., Yoshida S., Abe M., et al. A new calcilytic compound, JTT-305, inhibits enhanced signaling by activating mutations of calcium-sensing receptor in autosomal dominant hypocalcemia (ADH) [Abstract A09003241], ASBMR 31st Annual Meeting. J Bone Miner Res 2010, 24(Suppl 1). Available at, Accessed August 10, 2010. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=43414974-0eb2-4cd2-b072-185fc673ede7.